Velcade sNDA seeks full approval, second-line use
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.